(Q39067365)

8 September 2017

Treatment of chronic hepatitis B infection-2017. (English)

1 reference

8 September 2017

1 reference

1 reference

Guo-Feng Chen

1

1 reference

PubMed ID

28052634

8 September 2017

Cheng Wang

series ordinal

2

1 reference

PubMed ID

28052634

8 September 2017

George Lau

series ordinal

3

1 reference

8 September 2017

1 January 2017

1 reference

8 September 2017

1 reference

8 September 2017

37 Suppl 1

1 reference

8 September 2017

59-66

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

8 September 2017

1 reference

Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies

21 January 2018

1 reference

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

21 January 2018

1 reference

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

21 January 2018

1 reference

AASLD guidelines for treatment of chronic hepatitis B.

21 January 2018

1 reference

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

21 January 2018

1 reference

The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

21 January 2018

1 reference

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.

21 January 2018

1 reference

Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.

21 January 2018

1 reference

Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.

21 January 2018

1 reference

Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.

21 January 2018

1 reference

Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update

21 January 2018

1 reference

Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation

21 January 2018

1 reference

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis

21 January 2018

1 reference

Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.

21 January 2018

1 reference

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

21 January 2018

1 reference

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

21 January 2018

1 reference

Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

21 January 2018

1 reference

Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg.

21 January 2018

1 reference

Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients

21 January 2018

1 reference

Hepatitis B reactivation after chemotherapy: two decades of clinical research

21 January 2018

1 reference

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

21 January 2018

1 reference

Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.

21 January 2018

1 reference

Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents

21 January 2018

1 reference

Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function

21 January 2018

1 reference

New therapies for chronic hepatitis B.

21 January 2018

1 reference

Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.13309

1 reference

8 September 2017

1 reference

PubMed ID

28052634